| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 56.17 | 18.3% |
| Total Income | 57.89 | 10.0% |
| Expenditure | 49.64 | 17.4% |
| PBT | 8.25 | 20.3% |
| Net Profit | 5.62 | 34.8% |
| OPM | 7.68% | 1.32pp |
| NPM | 9.70% | 6.66pp |
| EPS | 3.71 | 30.8% |
Kilitch Drugs Limited Reports 222% YoY Rise in Q3 FY25 Consolidated PAT to Rs. 5.61 Crore
12 Feb 2025 · 12 Feb 2025, 08:30 pm
Summary
Kilitch Drugs Limited, a leading pharmaceutical company, announced its unaudited financial results for the quarter and nine months ended 31st December 2024. The company reported a 222% YoY rise in consolidated profit after tax (PAT) for Q3 FY25 to Rs. 5.61 crore and a 77% YoY growth in revenue from operations to Rs. 56.17 crore.
Key Highlights
- 1
Q3FY25 consolidated PAT surged by 222% YoY to Rs. 5.61 crore
- 2
Revenue from operations in Q3FY25 rose by 77% YoY to Rs. 56.17 crore
- 3
Standalone PAT in Q3FY25 increased by 25% YoY to Rs. 6.88 crore
- 4
Standalone revenue in Q3FY25 grew by 56% YoY to Rs. 46.51 crore
- 5
9MFY25 net profit rose by 42% YoY to Rs. 19.78 crore
- 6
9MFY25 revenue from operations increased by 35% YoY to Rs. 125.28 crore
Management Comments
Mr. Mukund Mehta
We witnessed significant growth in our performance this quarter; revenue from operations grew by 35% on standalone basis. We remain focused on driving sustainable growth and delivering strong returns for our stakeholders.
Informational and educational content only. Not investment advice.